Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 254-463-0 | CAS number: 39455-80-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Key studies demonstrate acute toxicity via the oral and inhalation route, however not via the dermal route:
Data are read-across from structural analogues, i.e. sodium trivanadium octaoxide and ammonium trivanadium octaoxide, based on inertness and similar solubility or lack thereof.
Two reliable studies by Wolf (2006a,b) were conducted with sodium trivanadium octaoxide and ammonium trivanadium octaoxide. The LD50 was determined to be 500 mg/kg bw for sodium trivanadium octaoxide and 200 mg/kg bw for ammonium trivanadium octaoxide. Using a worst case scenerio approach, the LD50 of 200 mg/kg bw will finally be used to cover this endpoint.
Two reliable studies by Weniger (2006a,b) were conducted with sodium trivanadium octaoxide and ammonium trivanadium octaoxide. The LC50 (male are the sensitive species) was determined to be 1.18 mg/L air (analytical) for sodium trivanadium octaoxide and 0.67 mg/L air for ammonium trivanadium octaoxide. Using a worst case scenerio approach, the LC50 of 0.67 mg/L air will finally be used to cover this endpoint.
Two reliable studies by Bernat (2006a,b) were conducted with sodium trivanadium octaoxide and ammonium trivanadium octaoxide. The LD50 was determined to be greater than 2000 mg/kg bw for both vanadium compounds.
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 200 mg/kg bw
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LC50
- Value:
- 670 mg/m³ air
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- discriminating dose
- Value:
- 2 000 mg/kg bw
Additional information
Read across
Upon dissolution, vanadium substances transform inartificial body fluids, including PBS, sweat, gastric juice and lung fluid, predominantlyto the pentavalent form,exceptin artificial lysosomal fluid; here, even pentavalent forms are converted almost completely to tetravalent species already after a short period of time (for more information on in vitro bioaccessibility testing,please refer IUCLID section 7).Thus, it can be assumed that vanadium speciation in body fluids is controlled by the conditions of the respective medium but not by the vanadium source. Thus, read-across of skin sensitisation data from soluble tetra- and pentavalent vanadium substances is justified.
a) Ammonia/ammonium (i) is ubiquitous in the environment (air, soil and water) and as part of the natural nitrogen cycle intrinsically present in the human body due to a natural background in all dietary sources, and (ii) ammonia/ammonium is a normal constituent of all body fluids. The sources of endogenous ammonium include bacterial hydrolysis of urea and other nitrogenous compounds in the intestine, the purine-nucleotide cycle, amino acid transamination in skeletal muscle, and other metabolic processes in kidneys and liver. At physiological pH, it exists mainly as ammonium ion with reference serum levels just below 35 µmol/L. Any excess ammonia is excreted as urea, which is synthesised in the liver through the urea cycle.
b) Sodium is (i) ubiquitous in the environment (air, soil and water), (ii) a key nutrient and intrinsically present in the human body due to a natural background in all dietary sources, and (iii) a normal constituent of all body fluids and a main blood mineral. Sodium is necessary for humans to maintain the balance of the physical fluids system and is required for nerve and muscle functioning. In consequence, because of the intrinsic nature of sodium as endogenous physiological compound, any skin sensitising effect of sodium is not to be expected.
As consequence, any effects observed in human health studies based on the vanadium ion and not on the cation.
Justification for selection of acute toxicity – oral endpoint
Two studies, conducted with sodiumpolyvanadate and ammoniumpolyvanadate, were used for read across to ammonium sodium vanadium oxide. The worst case value are reported in the field “effect level”.
Justification for selection of acute toxicity – inhalation endpoint
Two studies, conducted with sodiumpolyvanadate and ammoniumpolyvanadate, were used for read across to ammonium sodium vanadium oxide. The worst case value are reported in the field “effect level”.
Justification for selection of acute toxicity – dermal endpoint
Two studies, conducted with sodiumpolyvanadate and ammoniumpolyvanadate, were used for read across to ammonium sodium vanadium oxide.
Justification for classification or non-classification
The available information indicates that ammonium sodium vanadium oxide is acutely toxic via the oral and inhalation route, but not acutely toxic or harmful via the dermal route. Ammonium sodium vanadium oxide requires classification as toxic if swallowed (R25) and toxic by inhalation (R23) according to Directive67/548/EEC. Furthermore, ammonium sodium vanadium oxide requires classification as toxic if swallowed (Category 3) and toxic if inhaled (Category 3) according to Regulation (EC) 1272/2008. Classification of ammonium sodium vanadium oxide for acute toxicity via the dermal route is not required according to Directive 67/548/EEC andRegulation (EC) 1272/2008.
Specific target organ toxicant (STOT) – single exposure: oral and inhalation
The classification criteria according to regulation (EC) 1272/2008 as specific target organ toxicant (STOT) – single exposure, oral and inhalation are not met since reversible or irreversible adverse health effects (local or/and systemic) were not observed below lethal levels in addition to this effects which were responsible for the death of the animals. Hence, classification is not required.
Specific target organ toxicant (STOT) - single exposure: dermal
The classification criteria according to Regulation (EC) 1272/2008 as specific target organ toxicant (STOT) – single exposure dermal are not met since any adverse health effects, including reversible and irreversible, were not observed immediately or delayed after exposure.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.